Relationship between tumour angiogenesis and expression of cyclo-oxygenase-2 and vascular endothelial growth factor-A in human renal cell carcinoma

Journal of International Medical Research

Volumn 43, Issue 1, 2015, Pages 110-117

  Yang, Sheng ^a,b   Gao, Qin ^a   Jiang, Wei ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Fujian Provincial Key Laboratory of Stem Cell Engineering and Regenerative Medicine   (China)

Author keywords

cyclooxygenase 2; immunohistochemistry; prostaglandin endoperoxide synthase 2 (prostaglandin G H synthase and cyclo oxygenase); Renal cell carcinoma; vascular endothelial growth factor A

Indexed keywords

CYCLOOXYGENASE 2; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VON WILLEBRAND FACTOR; PTGS2 PROTEIN, HUMAN; VEGFA PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CAPILLARY DENSITY; CARCINOMA; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GRANULAR CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; MICROVASCULATURE; PROTEIN EXPRESSION; TUMOR ANGIOGENESIS; VERY ELDERLY; ENZYMOLOGY; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922314821     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060514545799     Document Type: Article

References (39)

1. Bedke J,Stenzl A.Renal cell carcinoma: recent developments in diagnostics and therapy.Urologe A. 2010;49:178-184
2. Cao Y,Prescott SM.Many actions of cyclooxygenase-2 in cellular dynamics and in cancer.J Cell Physiol. 2002;190:279-286
3. Singh B,Lucci A.Role of cyclooxygenase-2 in breast cancer.J Surg Res. 2002;108:173-179
4. Hiraga T1,Myoui A,Choi ME, et al.Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.Cancer Res. 2006;66:2067-2073
5. Hashimoto Y,Kondo Y,Kimura G, et al.Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma.Histopathology. 2004;44:353-359
6. Tsujii M,Kawano S,DuBois RN.Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.Proc Natl Acad Sci USA. 1997;94:3336-3340
7. Liu J,Yu JP,Wang XL, et al.[The role of cyclooxygenase-2 and vascular endothelial growth factor-C in lymphatic metastasis of gastric cancer].Zhonghua Nei Ke Za Zhi. 2004;43:841-844. [In Chinese, English abstract]
8. Fosslien E.Molecular pathology of cyclooxygenase-2 in neoplasia.Ann Clin Lab Sci. 2000;30:3-21
9. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Eble JNSauter GEpstein JI, ed. Lyon: IARC; 2004:12-43.
10. Robson CJ,Churchill BM,Anderson W.The results of radical nephrectomy for renal cell carcinoma.J Urol. 1969;101:297-301
11. Hastürk S,Kemp B,Kalapurakal SK, et al.Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma.Cancer. 2002;94:1023-1031
12. Kase S,Osaki M,Honjo S, et al.Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas.Virchows Arch. 2003;442:129-135
13. Weidner N,Folkman J,Pozza F, et al.Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.J Natl Cancer Inst. 1992;84:1875-1887
14. Xu XC.COX-2 inhibitors in cancer treatment and prevention, a recent development.Anticancer Drugs. 2002;13:127-137
15. Shono T,Tofilon PJ,Bruner JM, et al.Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.Cancer Res. 2001;61:4375-4381
16. Kankuri-Tammilehto MK,Söderström KO,Pelliniemi TT, et al.Prognostic evaluation of COX-2 expression in renal cell carcinoma.Anticancer Res. 2010;30:3023-3030
17. Huang ZF,Massey JB,Via DP.Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in human in vitro differentiated macrophages.Biochem Pharmacol. 2000;59:187-194
18. Howe LR,Subbaramaiah K,Brown AM, et al.Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.Endocr Relat Cancer. 2001;8:97-114
19. Rüegg C,Zaric J,Stupp R.Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality.Ann Med. 2003;35:476-487
20. Ragel BT,Jensen RL,Gillespie DL, et al.Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.Cancer. 2007;109:588-597
21. Basu GD,Pathangey LB,Tinder TL, et al.Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.Breast Cancer Res. 2005;7:R422-R435
22. Uefuji K,Ichikura T,Mochizuki H.Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer.Clin Cancer Res. 2000;6:135-138
23. Chang SH1,Liu CH,Conway R.Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression.Proc Natl Acad Sci USA. 2004;101:591-596
24. Liu XH,Kirschenbaum A,Yao S, et al.Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.Clin Exp Metastasis. 1999;17:687-694
25. Mungan MU,Gurel D,Canda AE, et al.Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma.Eur Urol. 2006;50:92-97
26. Khan KN,Stanfield KM,Trajkovic D, et al.Expression of cyclooxygenase-2 in canine renal cell carcinoma.Vet Pathol. 2001;38:116-119
27. Tuna B,Yorukoglu K,Gurel D, et al.Significance of COX-2 expression in human renal cell carcinoma.Urology. 2004;64:1116-1120
28. Sozen S,Gurocak S,Erdem O, et al.Cyclooxygenase-2 expression: does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma?.Int Urol Nephrol. 2008;40:295-301
29. Maráz A.Novelties in the treatment for advanced renal-cell cancer.Orv Hetil. 2011;152:655-662
30. Ishikawa Y,Aida S,Tamai S, et al.Significance of lymphatic invasion and proliferation on regional lymph node metastasis in renal cell carcinoma.Am J Clin Pathol. 2007;128:198-207
31. Dirim A,Haberal AN,Goren MR, et al.VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value.Int Urol Nephrol. 2008;40:861-868
32. Bamba H,Ota S,Kato A, et al.Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells.Biochem Biophys Res Commun. 2000;273:485-491
33. Zhang N,Gong K,Yang XY, et al.Expression of hypoxia-inducible factor-1-alpha, hypoxia-inducible factor-2alpha and vascular endothelial growth factor in sporadic clear cell renal cell renal cell carcinoma and their significance in the pathogenesis thereof.Zhonghua Yi Xue Za Zhi. 2006;86:1526-1529
34. Hemmerlein B,Kugler A,Ozisik R, et al.Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas.Virchows Arch. 2001;439:645-652
35. Kanayama H,Yano S,Kim SJ, et al.Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice.Clin Exp Metastasis. 1999;17:831-840
36. Rini BI,Campbell SC,Escudier B.Renal cell carcinoma.Lancet. 2009;373:1119-1132
37. Bartsch G,Eggert K,Soker S, et al.Combined antiangiogenic therapy is superior to single inhibitors in a model of renal cell carcinoma.J Urol. 2008;179:326-332
38. Singer EA,Gupta GN,Srinivasan R.Update on targeted therapies for clear cell renal cell carcinoma.Curr Opin Oncol. 2011;23:283-289
39. van der Veldt AA,Haanen JB,van den Eertwegh AJ, et al.Targeted therapy for renal cell cancer: current perspectives.Discov Med. 2010;10:394-405